283 related articles for article (PubMed ID: 30033395)
1. Dosing challenges in respiratory therapies.
Yeung S; Traini D; Lewis D; Young PM
Int J Pharm; 2018 Sep; 548(1):659-671. PubMed ID: 30033395
[TBL] [Abstract][Full Text] [Related]
2. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
3. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
4. Dry powder inhalation: past, present and future.
de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
[TBL] [Abstract][Full Text] [Related]
5. Dry powders for oral inhalation free of lactose carrier particles.
Healy AM; Amaro MI; Paluch KJ; Tajber L
Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
[TBL] [Abstract][Full Text] [Related]
6. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
Stegemann S; Faulhammer E; Pinto JT; Paudel A
Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
[TBL] [Abstract][Full Text] [Related]
7. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
8. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
9. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
10. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
Rawal T; Kremer L; Halloum I; Butani S
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
[TBL] [Abstract][Full Text] [Related]
11. Assessing Aerosol Performance of a Dry Powder Carrier Formulation with Increasing Doses Using a Novel Inhaler.
Yeung S; Traini D; Tweedie A; Lewis D; Church T; Young PM
AAPS PharmSciTech; 2019 Jan; 20(3):94. PubMed ID: 30690674
[TBL] [Abstract][Full Text] [Related]
12. Limitations of high dose carrier based formulations.
Yeung S; Traini D; Tweedie A; Lewis D; Church T; Young PM
Int J Pharm; 2018 Jun; 544(1):141-152. PubMed ID: 29649519
[TBL] [Abstract][Full Text] [Related]
13. Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend.
Wauthoz N; Hennia I; Ecenarro S; Amighi K
Int J Pharm; 2018 Dec; 553(1-2):47-56. PubMed ID: 30321640
[TBL] [Abstract][Full Text] [Related]
14. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
15. Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties.
Ambrus R; Benke E; Farkas Á; Balásházy I; Szabó-Révész P
Eur J Pharm Sci; 2018 Oct; 123():20-27. PubMed ID: 30016647
[TBL] [Abstract][Full Text] [Related]
16. Technological and practical challenges of dry powder inhalers and formulations.
Hoppentocht M; Hagedoorn P; Frijlink HW; de Boer AH
Adv Drug Deliv Rev; 2014 Aug; 75():18-31. PubMed ID: 24735675
[TBL] [Abstract][Full Text] [Related]
17. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
18. Challenges for pulmonary delivery of high powder doses.
Sibum I; Hagedoorn P; de Boer AH; Frijlink HW; Grasmeijer F
Int J Pharm; 2018 Sep; 548(1):325-336. PubMed ID: 29991452
[TBL] [Abstract][Full Text] [Related]
19. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
